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Abstract 1 
We evaluated the effect of hypothermia on the in vivo pharmacokinetics of midazolam 2 
(MDZ), with a focus on altered metabolism in the liver and binding to serum proteins. 3 
Rat primary hepatocytes were incubated with MDZ (which is metabolized mainly by 4 
CYP3A2) at 37, 32, or 28°C. The Michaelis–Menten constant (Km) and maximum 5 
velocity (Vmax) of MDZ were estimated using the Michaelis–Menten equation. The Km of 6 
CYP3A2 MDZ remained unchanged, but the Vmax decreased at 28°C. In rats, whose 7 
temperature was maintained at 37, 32, or 28°C by a heat lamp or ice pack, plasma 8 
concentrations of MDZ were higher, whereas those in the brain and liver were unchanged 9 
at 28°C. Tissue/plasma concentration ratios were, however, increased significantly. The 10 
unbound fraction of MDZ in serum at 28°C was half that at 37°C. These pharmacokinetic 11 
changes associated with hypothermic conditions were due to reductions in CYP3A2 12 
activity and protein binding.  13 
3 
INTRODUCTION 1 
“Therapeutic hypothermia” (TH) is the recommended regimen for adult subjects after 2 
cardiac arrest and in neonates with hypoxic ischemic encephalopathy [1, 2]. Several 3 
clinical studies have reported the benefits of TH (e.g., neuroprotection [3]). However, side 4 
effects found to be associated with TH include arrhythmia, dysfunction of blood 5 
coagulation, and impaired immune functions [4]. Remedies are needed to negate these 6 
side effects or provide sedation. However, changes in the pharmacokinetics of drugs such 7 
as midazolam (MDZ) [5, 6], phenytoin [7], or vecuronium [8] have been reported under 8 
hypothermic conditions. The mechanisms responsible for changes in the 9 
pharmacokinetics of drugs under hypothermic conditions have not been clarified fully. 10 
MDZ was selected for the present study because it is used frequently for sedation 11 
during TH [5, 6] and is metabolized by cytochrome P450 (CYP)3A4 in the human liver. 12 
CYP3A4 is known to metabolite ≈50% of drugs in use today [9]. In the present study, we 13 
evaluated CYP3A2 activity under hypothermia because it is a major component of the 14 
CYP3A family, and because its sequence is ≈90% identical and functionally equivalent 15 
to that of human CYP 3A4 [10–12]. CYP3A1 is present at low levels in normal untreated 16 
rats but CYP3A2 accounts for ≈25% of total CYP450 in rat livers [11]. We evaluated 17 
factors affecting the pharmacokinetics of MDZ to clarify the effects of hypothermia 18 
4 
(defined as a change in temperature from 37°C to 32°C and 28°C in the present study) on 1 
drugs metabolized by CYP3A in rats. Typically, TH is carried out at 32–34°C in clinical 2 
settings, so determination of alternations in the hepatic disposition of drugs at 32°C is 3 
needed. We also induced hypothermia at 28°C to more thoroughly examine unexpected 4 
conditions (e.g., excessive cooling and the dependency of pharmacokinetic changes in 5 
MDZ) on body temperature in rats at three temperatures. 6 
We examined the effects of low temperatures on CYP3A2 activity using rat 7 
hepatocytes. We also evaluated MDZ disposition in rats to determine the factors affecting 8 
its pharmacokinetics under hypothermic conditions, and speculated if these were identical 9 
to those in humans.  10 
5 
MATERIALS AND METHODS 1 
Materials 2 
MDZ (Dormicum®) used for in vivo and protein binding studies was purchased from 3 
Astellas Pharma Inc. (Tokyo, Japan). MDZ (for in vitro study), diazepam, collagenase, 4 
soybean trypsin inhibitor, ethylene glycol tetraacetic acid, and Trypan Blue were from 5 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 1-Aminobenzotriazole (ABT) was 6 
obtained from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan) and Hanks solution was 7 
from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan). All other chemicals were of the 8 
highest purity available. 9 
 10 
Animals 11 
Male Wistar rats (180–210 g or 240–270 g) were housed in cages in an air-conditioned 12 
room and maintained on a standard laboratory diet (MF; Oriental Yeast, Co., Ltd., Tokyo, 13 
Japan) and water ad libitum. All animal experiments conformed to the Guidelines for 14 
Animal Experimentation of Nagasaki University (Nagasaki, Japan) and were approved 15 
by the Committee of Animal Experimentation of Nagasaki University (approval number: 16 
0506280443). 17 
6 
Preparation of rat hepatocytes and incubation of drugs with hepatocytes 1 
Isolated rat hepatocytes were prepared from the livers of male Wistar rats by 2 
collagenase perfusion using a method based on that of Seglen et al. [13].   3 
To investigate the effects of temperature on MDZ uptake into rat livers, isolated rat 4 
hepatocytes were diluted with Krebs–Henseleit buffer containing 5 mM ABT to inhibit 5 
MDZ metabolism by CYP3A2 (2.0×106 cells/mL) [14]. ABT has been reported to be a 6 
“suicide substrate” of CYP, and that inactivation of CYP is caused by heme alkylation, 7 
which requires enzyme catalysis. [15–17] MDZ was incubated with rat hepatocytes at 37, 8 
32, or 28°C while CYP3A activity was inhibited. Incubation was carried out 20, 60, 180, 9 
or 300 s after MDZ addition and the incubation sample centrifuged immediately at 15,000 10 
× g for 1 min at 4°C. MDZ concentration in the supernatant was determined. 11 
To investigate the effects of temperature on CYP3A2 activity, MDZ (0.25, 0.5, 1, 1.5, 12 
2.5, 5, 7.5, 10 µg/mL) was incubated with rat hepatocytes diluted with Krebs–Henseleit 13 
buffer (1.0×106 cells/mL) at 37, 32, or 28°C for 10 min. Preliminary experiments showed 14 
that the MDZ concentration decreased linearly for 10 min for each temperature (data not 15 
shown). After incubation, the sample was mixed with acetonitrile, centrifuged at 17,863 16 
× g at room temperature for 5 min, and the MDZ concentration in supernatants determined. 17 
The rate of metabolism (v) of MDZ in the incubation sample was calculated using the 18 
7 






where C0 and C10 are the concentration of MDZ at 0 min or 10 min, and V is the volume 5 
of incubation sample, respectively. 6 
The Michaelis–Menten constant (Km) and maximum velocity (Vmax) were obtained by 7 





Evaluation of MDZ pharmacokinetics 11 
Male Wistar rats (240–270 g) were anesthetized with sodium pentobarbital (50 mg/kg, 12 
i.p.). The left femoral artery was cannulated with a polyethylene tube (i.d. 0.25 mm; o.d. 13 
0.61 mm; Dual Plastics, Dural, NSW, Australia). 14 
Rats were divided into two groups: (i) a control group in which the rectal temperature 15 
was maintained at 37°C by a heat lamp throughout the procedure; (ii) a hypothermic 16 
group maintained at 32 or 28°C, and hypothermia was induced by external cooling with 17 
ice packs before drug administration. 18 
8 
MDZ (5 mg/kg) was injected into the jugular vein. For determination of the plasma 1 
concentration of MDZ, blood was collected at 2, 5, 10, 20, 30, 45, and 60 min from the 2 
heparinized cannula inserted into the femoral artery. Samples were centrifuged at 17,863 3 
× g at room temperature for 5 min. To determine the tissue concentration of MDZ, the 4 
liver and brain were excised at 1, 5, 15, 30, and 60 min. Excised tissues were weighed 5 
and homogenized in twofold volumes of their weight in pH 7.4 phosphate buffer. 6 
ABT (50 mg/kg) was pre-administered to rats through the femoral vein 1 h before 7 
MDZ administration to determine the effects of changes in CYP3A2 activity on MDZ 8 
pharmacokinetics in rats [18, 19]. MDZ (0.5 mg/kg) was administered to rats. 9 
 10 
Pharmacokinetic analyses 11 
The area under the plasma concentration–time curves (AUCp) and mean resistant time 12 
(MRTp) were calculated by numerical integration using a linear trapezoidal formula and 13 
extrapolation to infinite time based on a mono-exponential equation [20]. 14 
Total body clearance (CLtot) and distribution volume at steady state (Vss) were 15 
calculated via dose/AUCp and CLtot/MRTp, respectively. 16 
9 
 1 
Protein-binding study 2 
The protein-binding ratio of MDZ with rat serum was evaluated using the equilibrium 3 
dialysis method. The molecular weight cutoff of the dialysis membrane was 12,000–4 
14,000. Serum was collected from normal rats and stored at −80°C until experimentation. 5 
MDZ was mixed with rat serum (final concentration of MDZ: 100 µg/mL) and 1 mL of 6 
sample was added into the dialysis membrane bag. These bags were suspended in a beaker 7 
containing 300 mL of phosphate-buffered saline at 37, 32, or 28°C using a water bath 8 
with shaking. Equilibrium was attained in 18 h, and then MDZ concentrations inside and 9 
outside the dialysis membrane bag were determined. The unbound fraction ratio (fu) of 10 






where Cbuffer and Ctotal are MDZ concentrations outside and inside of the dialysis 14 
membrane bag, respectively. 15 
Assay 16 
The MDZ concentration was determined by high-performance liquid chromatography 17 
with ultraviolet detection using an established method [21]. The plasma sample or tissue 18 
10 
homogenate was mixed with 0.1 M NaOH and 20 µg/mL diazepam (internal standard) 1 
and then extracted by diethyl ether. Diethyl ether was evaporated under N2 gas at 49°C 2 
and the dried sample dissolved with the mobile phase (pH 4.7; acetic buffer:acetonitrile 3 
= 55:45 (v/v)). 4 
High-performance liquid chromatography was carried out under the following 5 
conditions: column, 5C18-MS-II; column temperature, 25°C; mobile phase, pH 4.7, acetic 6 
buffer:acetonitrile = 55:45 (v/v); flow rate, 1 mL/min; detector, SPD-20Av, 220 nm 7 
(Shimadzu, Kyoto, Japan). 8 
 9 
Statistical analyses 10 
Statistical comparisons were made using the Tukey test following an analysis of 11 
variance (ANOVA) or repeat-measure ANOVA. p < 0.05 compared with the control group 12 
(37°C) was considered significant. Data are the mean ± S.E. or S.D.  13 
11 
RESULTS  1 
Effect of temperature on MDZ metabolism in rat hepatocytes 2 
To determine the effects of temperature on CYP3A2 activity using rat hepatocytes, we 3 
evaluated MDZ uptake in hepatocytes at different temperatures. The MDZ concentration 4 
in supernatants decreased for each temperature grouping for each 20 s, and remained 5 
unchanged between a 20-s lapse in duration but at 300 s in the presence of a CYP3A2 6 
inhibitor. 7 
Figure 1 shows the Michaelis–Menten plot for MDZ elimination from rat hepatocytes. 8 
Km and Vmax at 37, 32, or 28°C were obtained from the Michaelis–Menten equation. No 9 
significant changes were observed in the Km at 37, 32, or 28°C (Table I). The Vmax of 10 
MDZ was ≈25% lower at 32°C and 40% lower at 28°C than that at 37°C. 11 
 12 
Evaluation of MDZ pharmacokinetics under hypothermic conditions 13 
Figure 2 shows the plasma concentration–time curves of MDZ after its intravenous 14 
administration to rats at different body temperatures. The plasma concentration of MDZ 15 
at 28°C was significantly higher than that at 37°C. The AUCp, MRTp, and CLtot of MDZ 16 
at each temperature are listed in Table II. The AUCp was 1.4- (32°C) and 2.3-fold (28°C) 17 
higher than that at 37°C, and a significant difference was observed between AUCp values 18 
12 
at 37°C and 28°C. The MRTp was not altered under hypothermic conditions. The CLtot 1 
was significantly lower at 32 and 28°C than that at 37°C and the distribution volume at 2 
steady state (Vss) was decreased significantly in a temperature-dependent manner. 3 
However, the in vivo CLint did not decrease according to body temperature (37°C: 4267 4 
mL/min/kg; 32°C: 5573 mL/min/kg; 28°C: 3987 mL/min/kg). Moreover, these values 5 
were almost twofold higher than the in vitro CLint (37°C: 2039 mL/min/kg, 32°C: 1912 6 
mL/min/kg; 28°C: 1598 mL/min/kg). 7 
 8 
Changes in MDZ pharmacokinetics when CYP3A2 was inhibited by ABT 9 
The plasma concentration–time curves of MDZ after its intravenous administration to 10 
rats at different body temperatures, with or without ABT, are shown in Figure 3. The 11 
plasma concentration of MDZ was higher at 28°C than at 37°C without ABT, and this 12 
change was also observed in the ABT treatment group. The AUCp of MDZ at 28°C 13 
without ABT was significantly higher than that at 37°C (Table III). The AUCp of MDZ at 14 
28°C with ABT was 1.7-times higher than that at 37°C, though this was not significantly 15 
different. The in vivo CLint with ABT was 1368 mL/min/kg at 37°C, 2514 mL/min/kg at 16 
32°C, and 1945 mL/min/kg at 28°C, and these values decreased compared with those 17 
without ABT. 18 
13 
Effect of temperature on MDZ distribution in the brain and liver 1 
Tissue concentration–time profiles of MDZ after its intravenous administration to rats 2 
at different body temperatures are shown in Figure 4. MDZ concentrations in the brain 3 
and liver remained unchanged under hypothermic conditions. Figure 5 shows the tissue-4 
to-plasma (T/P) ratios of MDZ after its intravenous administration to rats at different body 5 
temperatures. The T/P ratio of MDZ at 1 min after intravenous administration was 6 
decreased significantly in the brain at 32 and 28°C (37°C: 1.31 ± 0.24; 32°C: 0.75 ± 0.10; 7 
28°C: 0.68 ± 0.06) and this tendency was observed for 60 min.  8 
 9 
Alteration in the unbound fraction ratio of MDZ in rat serum at low temperatures 10 
The fu of MDZ in rat serum at 37, 32, or 28°C was determined using the equilibrium 11 
dialysis method. The fu of MDZ at 37°C was 2.4%, and was decreased significantly at 32 12 
and 28°C (32°C: 1.2%; 28°C: 1.0%).  13 
14 
DISCUSSION  1 
MDZ is used as a sedative and its excessive use has been associated with respiratory 2 
depression or death. The plasma concentration of MDZ has been shown to increase during 3 
hypothermia in humans [5, 6]. Therefore, MDZ administration to patients needs to be 4 
optimized during TH to negate these side effects. Hence, we examined the effects of 5 
temperature on MDZ metabolism in rat hepatocytes, and identified the factors responsible 6 
for alteration of its pharmacokinetics under hypothermic conditions. 7 
Rat hepatocytes were used to evaluate MDZ metabolism in the liver because its uptake, 8 
efflux, and metabolism can be evaluated in these cells using enzymes such as CYP [22–9 
24]. Initially, we evaluated the effects of temperature on MDZ uptake into rat hepatocytes 10 
because drugs are known to be metabolized after their uptake into rat hepatocytes [25]. 11 
The concentration of MDZ in the supernatant of the hepatocyte suspension decreased to 12 
≈0.3 µg/mL from 0.5 µg/mL within 20 s, and there were no significant differences 13 
between values at 37, 32, or 28°C. Studies have shown that transporters such as P-14 
glycoprotein or organic anion transporters are not involved in MDZ uptake into rat 15 
hepatocytes [26–28], and that MDZ can enter rat hepatocytes by passive diffusion. 16 
MDZ metabolism by rat hepatocytes was examined at 37, 32, or 28°C and the Km and 17 
Vmax of MDZ calculated from the Michaelis–Menten equation. The Km of MDZ was not 18 
15 
altered at each temperature, but the Vmax of MDZ at 28°C was 40% lower than that at 1 
37°C (Table I). MDZ is metabolized by CYP3A2 in rat hepatocytes, therefore our results 2 
suggest that CYP3A2 activity is reduced at low temperatures. Empey et al. also evaluated 3 
CYP3A2 activity at 33°C using microsomes obtained from a model of cardiac arrest in 4 
rats [29]. In their report, the Km of MDZ at 33°C was not significantly different from that 5 
at 37oC, whereas the Vmax was decreased significantly; those findings were consistent 6 
with the results obtained in the present study. Therefore, low temperatures could cause a 7 
reduction in the Vmax of MDZ without altering the affinity between CYP3A2 and MDZ. 8 
NADPH, NADPH-CYP reductase, and lipids are known to be required for metabolism 9 
by CYP [30]. Further study is needed to clarify the mechanisms of the change in Vmax 10 
under hypothermic conditions. 11 
We also examined the pharmacokinetics of MDZ under hypothermic conditions in rats 12 
to ascertain if alterations in CYP3A2 activity could influence the pharmacokinetics of 13 
MDZ. The plasma concentration of MDZ increased slightly in a body temperature-14 
dependent manner (Figure 2), and the AUCp of MDZ was significantly higher at 28°C 15 
than at 37°C (Table II). The CLtot of MDZ was significantly lower at 32 and 28oC than at 16 
37°C. The CLtot of MDZ is similar to hepatic blood flow because MDZ is a highly cleared 17 
compound. It has been reported that the blood flow is decreased under hypothermia [31]. 18 
16 
Hence, alterations in blood flow owing to temperature could also affect the CLtot. 1 
Moreover, the concentration of MDZ at 0 min estimated by analyses of a two-2 
compartment model was increased slightly under hypothermia (Figure 2) and the 3 
distribution volume of central compartment (Vc) was significantly lower at 28°C than at 4 
37°C (data not shown). In our previous study, the initial concentrations of several drugs 5 
(phenolsulfonphthalein, indocyanine green, fluorescein isothiocyanate-dextran, 4-6 
nitrophenol) after intravenous injection were also increased according to body 7 
temperature [31, 32]. Tveita et al. reported that blood volume and plasma volume were 8 
decreased post-hypothermia [33]. These alterations might affect the Vc of drugs and 9 
increase the initial concentration. 10 
To determine the effect of CYP3A2 activity on MDZ pharmacokinetics under 11 
hypothermia, we evaluated the pharmacokinetics of MDZ in rats when the activity of 12 
CYP3A2 was inhibited by ABT. ABT administration to rats has been shown to cause 13 
reductions in the content of CYP in the liver, and this effect is maintained for 1 h [15, 19]. 14 
MDZ (0.5 mg/kg) could negate the side effects of MDZ caused by high plasma 15 
concentration. Despite inhibition of CYP3A2 activity by ABT, the AUCp of MDZ at 28°C 16 
was ≈1.7-times greater than that at 37°C (Table III). In addition, the in vivo CLint with 17 
ABT was 1368 mL/min/kg at 37°C, 2514 mL/min/kg at 32°C, and 1945 mL/min/kg at 18 
17 
28°C. Furthermore, these values decreased compared with those observed without ABT. 1 
These results suggest that the pharmacokinetics of MDZ under hypothermic conditions 2 
could differ not only by reductions in the activity of CYP3A2, but also by decreases in 3 
Vss. 4 
The decrease in the Vss of MDZ under hypothermic conditions may have been caused 5 
by a reduction in tissue distribution, therefore we evaluated the concentration of MDZ in 6 
the brain and liver. Although the plasma concentration of MDZ was increased under 7 
hypothermic conditions (Figure 2), MDZ concentrations in the brain and liver remained 8 
unchanged (Figure 4). We also calculated the T/P of MDZ to evaluate the tissue 9 
distribution of MDZ under hypothermic conditions. The T/P was decreased significantly 10 
in the brain under hypothermic conditions. These results suggest that MDZ distribution 11 
in the brain was inhibited under hypothermic conditions, and this may have caused the 12 
reduction in Vss. In addition, reduced tissue binding of drug could cause the reduction of 13 
Vss since Vss = Vp+ summed Vt × fB/ft (where the Vt is distribution volume of tissue 14 
and ft is the unbound fraction in tissue). Further study is needed to determine effect of 15 
temperature on ft. Drugs reach organs by blood flow within organs and diffuse to organ-16 
only unbound fractions. Hence, the tissue distribution of drugs can be determined by 17 
organ blood flow, the protein-binding ratio, and cellular uptake [34–36]. Organ blood 18 
18 
flow is known to be lower under hypothermic conditions than at normal body temperature 1 
[37]. Our previous report also showed that hepatic blood flow was decreased ≈50% at 2 
32°C and 80% at 28°C, respectively, in rats [31]. Here, we showed that uptake of MDZ 3 
into rat hepatocytes was not altered under low temperatures, and that the fu of MDZ in rat 4 
serum was significantly lower at 32 and 28°C than at 37°C. In the present study, MDZ 5 
binding to proteins in the serum may not have become saturated because the protein 6 
binding of benzodiazepines has been shown not to be dependent on the drug concentration 7 
[38]. These results suggest that the reduction in blood flow and the fu of MDZ in rat serum 8 
could inhibit the tissue distribution of MDZ under hypothermic conditions. The effect of 9 
blood flow and protein binding on the tissue distribution of drugs on an individual level 10 
needs to be studied. In addition, an identical study using human hepatocytes and human 11 
albumin is needed to ascertain if these results are applicable for humans.  12 
19 
Conclusion 1 
 We demonstrated that a reduction in CYP3A2 activity and the unbound fraction 2 
ratio of MDZ in rat serum could cause changes in the pharmacokinetics of MDZ under 3 
hypothermic conditions. These results provide an insight into the optimization of drug 4 
administration under hypothermic conditions. 5 
 6 
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Figure legends 1 
Fig. 1 Michaelis–Menten plot for the elimination rate of MDZ in rat hepatocytes at 37, 32, and 2 
28°C. Each symbol is the mean ± S.E. of at least four experiments. Solid lines represent the result of 3 
the best fit by the least-square method; 37°C (○), 32°C (▲), and 28°C (□). 4 
 5 
  6 
24 
Fig. 2 Plasma concentration–time profiles of MDZ (5 mg/kg) after its intravenous administration 1 
to rats at different body temperatures. Each symbol is the mean ± S.E. of four experiments; 37°C 2 
(○), 32°C (▲), and 28°C (□). 3 
**p < 0.01, significantly different from value at 37°C. 4 
 5 
  6 
25 
Fig. 3 Plasma concentration–time profiles of MDZ (0.5 mg/kg) without ABT (A) or with ABT 1 
(B) after its intravenous administration to rats at different body temperatures. Each symbol is 2 
the mean ± S.E. of five experiments; 37°C (○), 32°C (▲), and 28°C (□). 3 
 4 
  5 
26 
Fig. 4 MDZ concentrations in the brain (A) and liver (B) after its intravenous administration to 1 
rats at 5 mg/kg at different body temperatures. Each point is the mean ± S.E. of at least four 2 
experiments; 37°C (○), 32°C (▲), and 28°C (□). 3 
 4 
  5 
27 
Fig 5. Tissue-to-plasma ratio in the brain of MDZ after its i.v. administration to rats at a dose of 1 
5 mg/kg under different body temperatures. Each bar represents the mean + S.E. of at least four 2 
experiments. 37°C (open column), 32°C (slashed column) and 28°C (closed column). *: p < 0.05, **: 3 
p < 0.01, significantly different from value at 37 °C. †: p < 0.05, significantly different from value at 4 
32°C. 5 
 6 
  7 
28 
Tables 1 
Table I Michaelis–Menten enzyme kinetic parameters in an MDZ-estimated in vitro metabolism 2 
study using rat hepatocytes at 37, 32, and 28°C 3 
 37°C 32°C 28°C 
Km (µg/mL) 1.66 ± 0.33 1.42 ± 0.31 1.54 ± 0.34 
Vmax (µg/min/106 cells) 0.32 ± 0.06 0.25 ± 0.05 0.19 ± 0.03 
Each value is the mean ± S.E. of at least four experiments.  4 
29 
Table II Moment parameters calculated by moment analyses for the plasma concentration–1 
time profiles of MDZ and pharmacokinetics parameters of MDZ at 5 mg/kg after its 2 
intravenous administration to rats at different body temperatures 3 
 37oC 32oC 28oC 
AUCp (µg • min/mL) 59.4 ± 2.54 84.7 ± 2.68* 134.5 ± 10.10**,†† 
MRTp (min) 34.9 ± 2.3 33.5 ± 3.5 36.7 ± 4.9 
CLtot (mL/min/kg) 84.7 ± 3.5 59.2 ± 1.8** 37.8 ± 3.0**,†† 
Vss (L/kg) 2.96 ± 0.22 1.97 ± 0.15* 1.39 ± 0.21** 
Each value is the mean ± S.E. of four experiments. 4 
*p < 0.05, **p < 0.01, significantly different from the value at 37°C. ††p < 0.01, significantly different 5 
from the value at 32°C.  6 
30 
Table III Area under the plasma–concentration time curves of MDZ after its intravenous 1 
administration to rats at 0.5 mg/kg with or without ABT at different body temperatures 2 
Each value is the mean ± S.E. of five experiments. 3 
**p < 0.01, significantly different from the value at 37°C. ††p < 0.01, significantly different from the 4 
value at 32°C. 5 
 37°C 32oC 28°C 
Without ABT (% of dose•min/mL) 5.39 ± 0.67 4.50 ± 0.26 11.13 ± 0.95**,†† 
With ABT (% of dose•min/mL) 12.87 ± 0.43 14.93 ± 2.38 21.40 ± 3.36 
